+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

Cancer 110(5): 965-972

BACKGROUND. The optimal trastuzurnab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. The trastuzurnab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare these regimens.METHODS. Eligible patients had HER2-overexpressing, metastatic breast cancer and had received no prior chemotherapy for advanced disease. Patients were randomized 1:1 to receive either trastuzumab with weekly vinorelbine therapy or weekly taxane therapy (paclitaxel or clocetaxel at the investigator's choice). Originally planned for 250 patients, the study was closed because of poor accrual with 81 evaluable patients, including 41 patients who received vinorelbine and 40 patients who received taxane.RESULTS. Response rates were 51% and 40% for the vinorelbine/trastuzumab arm and the taxane/trastuzumab arm, respectively (Fisher exact test; P = .37). The median time to disease progression was 8.5 months and 6.0 months for the vinorelbine- and taxane-based arms, respectively (log-rank test; P =.09). Treatment with either regimen generally was well tolerated, yielding comparable rates of neurologic and gastrointestinal toxicity. Vinorelbine-based treatment was associated with more anemia and neutropenia and with 2 episodes of cardiotoxicity Taxane-based therapy was associated with more dermatologic toxicity, myalgias, and fluid retention.CONCLUSIONS. Both vinorelbine/trastuzumab and taxane/trastuzurnab treatments were active as first-line therapy for HER2-positive, metastatic breast cancer and had comparable rates of efficacy and tolerability. The toxicities observed were the result of recognized side effects associated with each of the chemotherapy agents and schedules. These data can inform treatment decision making in this clinical setting. Cancer 2007;110:965-72. (c) 2007American Cancer Society.

(PDF emailed within 0-6 h: $19.90)

Accession: 017552506

Download citation: RISBibTeXText

PMID: 17614302

DOI: 10.1002/cncr.22885

Related references

Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. Journal of Clinical Oncology 24(18_suppl): 650-650, 2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet. Oncology 17(3): 357-366, 2016

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care 9(5): 344-348, 2015

The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer. Current Oncology 21(5): E723-E727, 2014

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1057-1057, 2016

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment 141(3): 437-446, 2014

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Journal of Breast Cancer 14(2): 140-146, 2011

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer 90(1): 36-40, 2004

Outcomes of re-treatment with first-line Trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant Trastuzumab: A prospective multicenter study. Oncotarget (): -, 2016

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Anti-Cancer Drugs 19(7): 753-759, 2008

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Annals of Oncology 22(3): 603-608, 2011

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 19(10): 2722-2730, 2001

Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients. Breast Cancer Research & Treatment 82(Supplement 1): S72, 2003

Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer. Nan Fang Yi Ke Da Xue Xue Bao 28(9): 1707-1709, 2008

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Cancer ChemoTherapy and Pharmacology 72(1): 109-115, 2013